How should multiple sclerosis be treated during the third trimester of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Multiple Sclerosis in the Third Trimester of Pregnancy

For women with MS in the third trimester, continue pregnancy-compatible disease-modifying therapies if needed for disease control, prioritizing interferon-beta, glatiramer acetate, or certolizumab, while avoiding NSAIDs entirely and using corticosteroids only for acute disabling relapses.

Disease Activity During Third Trimester

MS typically shows reduced relapse rates during the third trimester, with disease activity naturally suppressed by pregnancy-related immune changes 1, 2. However, this protective effect is not universal, and some patients experience relapses even during late pregnancy 3, 4. The key is balancing the natural disease suppression against individual risk of breakthrough activity.

Medication Management Strategy

First-Line Compatible Agents

Interferon-beta and glatiramer acetate are the safest options and can be continued throughout the third trimester if disease control requires ongoing therapy 1. These agents have the most extensive safety data in pregnancy and do not significantly cross the placenta.

Certolizumab is strongly recommended if biologic therapy is needed, as it lacks an Fc fragment and has minimal placental transfer even in the third trimester 5. This makes it uniquely suitable for continuation through delivery without neonatal drug exposure concerns.

Agents Requiring Careful Consideration

Natalizumab presents a complex risk-benefit scenario in the third trimester. While it can be continued for highly active MS when disease control outweighs risks, it crosses the placenta extensively after 20 weeks, leading to significant neonatal drug levels 6, 7. If used:

  • Expect mild-to-moderate hematologic abnormalities in 33-77% of newborns, including thrombocytopenia and anemia 6, 7
  • Ensure pediatric evaluation at delivery for potential complications
  • Consider dose spacing or discontinuation in the final weeks if disease is stable
  • Monitor cord blood natalizumab levels if available

Other monoclonal antibodies (adalimumab, infliximab, golimumab) undergo high placental transfer in the third trimester and should ideally be discontinued earlier in pregnancy. If disease is well-controlled, stop these agents in the third trimester 5. However, if disease remains highly active, continuation may be justified with neonatal monitoring.

Strictly Contraindicated Agents

NSAIDs must be completely avoided in the third trimester due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction 8, 5, 8, 5. This is a strong recommendation with clear fetal safety concerns.

Acute Relapse Management

For acute disabling relapses in the third trimester:

Intravenous methylprednisolone pulse therapy is the treatment of choice 3, 1. Use high-dose pulses (typically 1000mg daily for 3-5 days) rather than prolonged oral corticosteroids to minimize cumulative fetal exposure while effectively treating the relapse.

Plasmapheresis can be added for severe, steroid-refractory relapses 3. This is safe in the third trimester and provides an additional therapeutic option without medication-related fetal risks.

Avoid chronic oral corticosteroids - if doses exceed 20mg prednisone daily or prolonged use is needed, add pregnancy-compatible steroid-sparing agents rather than continuing high-dose steroids 5, 9, 5. Chronic corticosteroid exposure carries risks of gestational diabetes, preterm birth, and maternal infections 8.

Monitoring and Delivery Planning

  • MRI without gadolinium is safe for monitoring disease activity if clinically indicated 1
  • MS does not dictate mode of delivery unless significant disability affects maternal effort 1
  • Coordinate care with high-risk obstetrics and neurology
  • Plan for postpartum period, as relapse risk increases substantially in the first 3 months after delivery 3, 1, 2

Critical Pitfalls to Avoid

  1. Do not reflexively discontinue all DMTs - some patients require ongoing therapy, and pregnancy-compatible options exist
  2. Never use NSAIDs for symptom management in the third trimester
  3. Do not delay treatment of acute relapses - methylprednisolone is safe and effective when needed
  4. Avoid high-dose chronic corticosteroids - use pulse therapy for relapses instead
  5. Do not assume all biologics are equivalent - placental transfer varies dramatically (certolizumab minimal vs. natalizumab extensive)

References

Related Questions

What laboratory tests should be ordered to evaluate a possible multiple sclerosis relapse?
Can progression of multiple sclerosis (MS) lead to hallucinations or progressive dementia?
Can patients with multiple sclerosis present with headache?
Can a patient experience a flare (relapse) of multiple sclerosis?
Could bilateral arm paresthesia be a sign of multiple sclerosis?
Is dosing loperamide every six hours equivalent to four doses per day?
What complications can occur after a transperineal ultrasound-guided prostate biopsy performed without an identifiable target lesion?
What are the possible causes of episodic unilateral vestibular weakness in a patient with a history of supraventricular tachycardia (SVT)?
Can I instruct an adult patient to take two tablets (4 mg) of loperamide initially, then one tablet (2 mg) by mouth every six hours as needed for diarrhea?
Is it appropriate to give an adult with uncomplicated acute diarrhea an initial dose of two loperamide tablets (4 mg) followed by one tablet (2 mg) every four hours as needed, not exceeding eight tablets in 24 hours?
What are the appropriate dosing, contraindications, and adverse effects of polyethylene glycol (PEG) for treating constipation and for bowel preparation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.